The FAVOR III China trial found that lesion selection for percutaneous coronary intervention (PCI) using the non-invasively assessed physiologic measurement quantitative flow ratio (QFR) improved outcomes for PCI compared with a standard angiography-guided strategy.
Smokers needed their blocked arteries fixed nearly a decade earlier than non-smokers, and patients with obesity underwent these procedures four years earlier than non-obese patients, according to a new study from across Michigan.
While some studies suggest female patients treated by female physicians have better outcomes, there does not appear to be a relationship between operator and patient gender and outcome in patients undergoing coronary angioplasty or stenting.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
All educational programming from TCT Connect will be available to registrants for free through October 18, 2021. TCT is the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine.
The Cardiovascular Research Foundation (CRF) has announced that the 2021 Chronic Total Occlusion (CTO) Summit will now take place as a virtual event called CTO Connect. It will take place online February 20-21, 2021.
The conference will feature live case transmissions performed by some of the world’s leading operators along with real-time analysis from world-class faculty members. Live and on-demand sessions will also highlight engaging case-based discussions, challenging cases, and the latest technical developments and refinements in CTO PCI.
The OPTIMIZE randomized trial comparing a novel, low-profile drug-eluting stent (DES) facilitating transradial access (TR) and direct stenting (DS) to existing DES did not establish non-inferiority of the new stent based on the prespecified study statistical analysis plan, likely due to the definition of periprocedural target vessel myocardial infarction (TVMI) coupled with a large proportion of high-sensitive cardiac troponin assays used in the trial.
For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy.
A new observational study of deferred lesions following combined fractional flow reserve (FFR) and coronary flow reserve (CFR) assessments found that untreated vessels with abnormal FFR but intact CFR do not have non-inferior outcomes compared to those with an FFR greater than 0.8 and a CFR greater than or equal to two when treated medically.
Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ≥0.90, it reduced the proportion of patients with a residual FFR ≤0.80 following PCI.
An individual patient data pooled analysis comparing the use of bivalirudin versus heparin in heart attack patients undergoing percutaneous coronary intervention (PCI) found that bivalirudin use was associated with similar overall rates of 30-day mortality across all heart attack patients, but lower rates of serious bleeding events. Moreover, mortality was reduced in patients with ST-segment elevation myocardial infarction (STEMI) who were treated with a post-PCI bivalirudin infusion.
The TCT Connect agenda is now available online. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18. Every year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the globe to present and discuss the latest evidence-based research in the field.
The Cardiovascular Research Foundation (CRF) has announced over 30 late-breaking trial and science presentations that will be reported at TCT Connect. TCT, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place online October 14-18.
The Cardiovascular Research Foundation (CRF) is pleased to announce that registration for the annual scientific symposium, TCT Connect, taking place online October 14-18, is free for all attendees and is now open.
The Cardiovascular Research Foundation (CRF) has announced that Transcatheter Cardiovascular Therapeutics (TCT) 2020 will now take place as a virtual event called TCT Connect. The event will take place online October 14-18, 2020 and feature live case-based transmissions from around the globe, late-breaking clinical trials and science, virtual training, and countless opportunities to learn and engage with the brightest minds in interventional cardiovascular medicine.
The most common type of heart disease ― coronary artery disease ― affects 6.7% of adults and accounts for 20% of 2 in 10 deaths of adults under age 65. The condition builds over time as inflammation and cholesterol-containing plaques settle in the heart’s arteries, where they can eventually cause narrowing and blockages that lead to a heart attack.
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.
New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT).
New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe and effective compared to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT in patients undergoing PCI for unprotected left main coronary artery (uLMCA) disease.